An antibody therapy against a key inflammatory molecule involved in migraines reduces the number of headaches that chronic migraine patients experience per month in a phase III trial
A new study of fremanezumab, an immunotherapy that counteracts one of the molecules released during migraine, was found successful in reducing the number of days that chronic migraine sufferers experienced headaches. The results of the phase III clinical trial were published November 29, 2017 in the New England Journal of Medicine.
The World Health Organization estimates that between 127 and 300 million people around the world experience chronic migraine, defined as 15 or more headaches per month for at least three months. The disease can be debilitating and although a number of interventions exist, many only work for a certain time before they fail to prevent or relieve pain.
“This therapeutic approach offers new hope for people whose migraines cannot be treated with existing medicine,” says Stephen D. Silberstein, M.D., principal investigator of the HALO CM trial, Professor of Neurology and Director of the Jefferson Headache Center at the Vicki & Jack Farber Institute for Neuroscience at Thomas Jefferson University Hospital. “Our worldwide effort to evaluate this novel therapeutic approach has shown positive results and was safe in patients.”
Fremanezumab, a monocolonal antibody developed by Teva Pharmaceuticals, is a biological agent that binds to and blocks the action of a migraine-associated protein called calcitonin gene-related peptide (CGRP). Mounting evidence of its importance in migraines has made CGRP a focal point of research and drug development. The peptide is released at high levels during migraine in response to inflammation, and triggers a cascade effect that stimulates more CGRP release. This results in increasing sensitivity of the brain to pain. By blocking this peptide, doctors hope to break the cycle of increasing inflammation and increased pain sensitivity that contributes to migraine headaches.
Researchers from 132 sites across nine countries enrolled 1130 patients and randomly assigned them to one of three groups: one that received quarterly treatments, a group that received one treatment per month, and one that received placebo injections. The trial lasted for 16 weeks, with a 12-week treatment window.
The results of the trial show that treatment with fremanezumab reduced the number of days patients experience headache by an average of 4.3 days with quarterly treatment and 4.6 days with monthly treatment. “We saw some patients with 100 percent reduction in migraine, others with 75 percent reduction,” says Dr. Silberstein. The level of response varied between patients.
The researchers also looked at how well the therapy worked relative to each patient’s headache burden. They calculated the percent of patients who had more than a 50 percent reduction in the number of days they experienced either a severe or moderate headache per month. Using this measure, the researchers saw that 37.6 percent of patients on the monthly regimen, and 40.8 percent on the quarterly regimen had at least a 50 percent reduction in the number of moderate headaches per month, compared to 18.1 percent in the placebo group.
The therapy had a favorable safety profile with the most common adverse event reported as irritation at injection site, which was reported in the placebo group as well.
“If approved, this treatment would provide physicians with an important new tool to help prevent migraine, reduce a patient’s migraine load, and potentially help patients return to normal” says Dr. Silberstein.
The Latest on: Migraines
- Meghan Markle health: The Duchess on her hidden 'debilitating' illnesson August 9, 2022 at 10:09 am
MEGHAN MARKLE, who turned 41 earlier this week on August 4, is an advocate, not only for humans rights, but for leading a healthy lifestyle. A fan of yoga, meditation and sweet potato fries, you might ...
- 6 Reasons Your Migraines Might Get Worse With Age and What to Do About Iton August 7, 2022 at 7:02 am
Certain lifestyle factors related to aging could make your migraines worse the older you get. Here's why, how to find migraine relief and when to see a doctor.
- More than a mere headache: how migraines affect your lifeon August 6, 2022 at 5:00 pm
This incapacitating neurological disorder can afflict men, women and children, though the vast majority of suffers are female.
- Shoppers Have Been Buying Multiple Of This $10 Massage Tool for Battling Migraineson August 6, 2022 at 10:39 am
Whether it be a tension headache or a migraine, they can stop your life instantly, making you turn into a ball of pain that craves darkness and no sound. To put it bluntly, it sucks. Per Mayo Clinic, ...
- What Happens To Your Body When You Have A Migraineon August 6, 2022 at 4:00 am
A migraine is a type of headache that's sometimes on just one side of the head. A migraine "attack" can come on and last for a few hours to a few days.
- Shoppers Say This Cooling & Comfortable Migraine-Relief Tool ‘Changed Their Life’on August 3, 2022 at 1:55 pm
In case you didn’t know already, we hate migraines. They’re debilitating and unbelievably painful, putting our entire lives on pause instantly. Migraine.com said that some studies found that around ...
- The #1 Thing You Need to Do If You Get a Migraine at Homeon August 2, 2022 at 10:59 am
If you’re part of the estimated 12% of the population that gets migraines, you know they can be debilitating. When you’re in the midst of an attack and suffering from migraine symptoms like aura, ...
- Do your migraines feel worse during the summer? Here's whyon August 1, 2022 at 8:58 am
DALLAS — If you or someone you know suffers from migraines, you might have noticed that they seem to get worse during the summer. "Weather is a very important factor and element when it comes to ...
- PIP: Britons could get up to £627 a month for migraines, headaches and other conditionson July 30, 2022 at 6:48 am
Government figures showed that 1,370 claimants suffer from headaches, while 3,260 people on PIP have migraines, and 1,485 are affected by dizziness. The support is available to people over the age of ...
- 10 Best CBD Oils for Migraineson July 27, 2022 at 6:00 pm
Migraines are one of the most common neurological disorders in the world. An estimated 38 million Americans suffer from migraines, according to the Migraine Research Foundation. And while there are ...
via Google News and Bing News